Development Time Sample Clauses

Development Time. First version of development cycle is 2008/01/02-2008/10/30
Sample 1
AutoNDA by SimpleDocs
Development Time. Appropriate soil survey work, subsurface analysis, traffic data and accident data must be collected. The preliminary surfacing recommendation using a minimum design life of 10 years will confirm the level of rehabilitation (minor or major). The data collection and engineering required to determine the level of rehabilitation should take six to nine months. Additional development time for a minor rehabilitation should be one and one half to two years, given the possible inclusion of other features. Americans With Disabilities Act: Install curb ramps wherever curb, gutter and sidewalk are adjacent to the project. Evaluate existing and potential pedestrian use to determine ramp locations, the need for sidewalk improvements, and the installation of additional sidewalk. Coordinate proposed improvements and any necessary exceptions with the ADA coordinator. Pavement Width: Interstate – Provide no less than 38 ft width w/5:1 surfacing inslopes. In mountainous terrain, a reduced shoulder width resulting in an overall top width of 36 ft w/5:1 surfacing inslopes may be considered. NHS – If the existing width exceeds the width described in the “Design Guidelines” memo dated August 5, 2008 (these widths are equal to the AASHTO roadway widths for arterials), reduce the top width to accommodate the overlay. If the resulting width will be less than the “Design Guidelines” width, steepen surfacing inslopes to no steeper than 4:1 before reducing the width. If the overlay cannot be accommodated by steepening the surfacing inslopes reduce the width to a minimum of 28 ft. If the placement of the overlay will result in a top width less than 28 ft., employ the Roadway Width Decision Process to determine if a lesser width can be utilized. STP (Primary) - If the existing width exceeds the width described in the “Design Guidelines” memo dated August 5, 2008 (note that these widths are different that the AASHTO roadway widths for collectors), reduce the top width to accommodate the overlay. If the resulting width will be less than the “Design Guidelines” width, steepen surfacing inslopes to no steeper than 4:1 before reducing the width. If the overlay cannot be accommodated by steepening the surfacing inslopes reduce the width to a minimum of 28 ft for ADT > 300, or a minimum of 24 ft. for ADT < 300. If the placement of the overlay will result in a top width less than 28 ft., employ the Roadway Width Decision Process to determine if a lesser width can be utilized. Widths less than ...
Sample 1
Development Time. This is a research program and unexpected challenges can arise at any time. ISE will notify Encore of any such challenges and potential resultant delays as early as possible. ISE understands the time sensitivity of the program and will make all reasonable attempts to minimize the development time of each Milestone. It is estimated that Phase A will take 6-9 months and that Phase B xxxx xake 9-12 months. Cost Increases -------------- Due to the research nature of this program, unexpected costs may arise at any time. ISE will notify Encore of any potential cost increases for any Milestone as they arise. Development Fee Schedule ------------------------ Encore shall pay ISE the following development fees in connection with the development of the MPG System: Development Phase A Milestones Fee ($) Milestone1-Review of literature 14,680 Milestone 2-Evaluate state of the art 19,720 Milestone 3-Cycle analysis 34,960 Milestone 4-Analyze key technologies 34,200 Milestone 5-Build air driven MPG System 54,200 Milestone 6-Test, analyze performance 43,320 Milestone 7-System Integration of MPG System 45,000 Milestone 8-Report and present 18,700 Phase A Subtotal $264,780 Phase B Milestones Milestone 9-Design model prototype MPG System 131,000 Milestone 10-Build prototype, test apparatus 244,200 Milestone 11-Run, data reduction, analyze 219,720 Milestone 12-Report and Present 30,900 Phase B Subtotal $625,820 Grand Total $890,600 ***** EXHIBIT B HUNT PATENT
Sample 1
Development Time. The period beginning with the execution of this agreement and ending with the delivery for acceptance testing of the first filter prototype to OPLINK.
Sample 1
Development Time. USSI will provide Customer with [*] StaffWeeks of CSM development (exclusive of travel, lodging, subsistence and communication expenses) for the charge of [*]. Travel, lodging, and subsistence expenses for USSI personnel performing any services away from USSI's Xxxxxx Lake facility, as well as communication expenses (including but not limited to, telephone, telefax, courier, express mail and dial-up data transmissions), are additional and are the responsibility of Distributor. [*] Confidential treatment has been requested with respect to the information contained within the "[*]" markings. Such marked portions have been omitted from this filing and have been filed separately with the Securities and Exchange Commission.
Sample 1
Development Time. 115 STAFFWEEK(S) ----------------
Sample 1
Development Time. ‌ An overview per year will be provided, showing: • Average development time for IEC standard • Average development time for EN IEC standard • Average development time for hEN IEC standard • Average development time for CENELEC homegrown EN • Average development time for CENELEC homegrown hEN • identification of number of late projects (CD - CDV - FDIS stages) 8 Annexes‌ Annex 1 Boomerang procedure‌ See attached document BT(SG)3996 of June 2000. CENELEC CLC/BT(SG)3996 June 2000 Document contents for discussion only and still to be approved 104 BT – Item 4.3.1 SUBJECT REFINED APPROACH TO THE BOOMERANG PROCEDURE Follow up of D103/151 BACKGROUND The comments and suggestions brought forward by CS on the practical implementation of the boomerang procedure (as defined in D102/159) had triggered the decision at 103 BT to reconvene the ad hoc WG for preparing a refined approach to the procedure based upon the comments received (ref. D103/151). The ad hoc WG “Boomerang” met on 5 June 2000 in Prague, under the convenorship of Dr R. Salffner (attendance list in Annex 1). As a first step the WG concentrated on the major proposed change, i.e. the simplification of the procedure by excluding all boomerang standards from parallel procedures. With this option there would be one and only one procedural way until IEC has finished its work and BT can make subsequently individual decisions on the implementation in Europe of boomerang IEC standards, on the basis of the advice from the relevant CLC/TC or SR. The WG agreed with this principle and resolved to recommend to BT the approval of the refined approach to the boomerang procedure as laid down in Annex 2. The discussion of the other comments and suggestions of CS led to the following guidelines in the context of the boomerang procedure : ∗ in case of coexistence of an EN 5XXXX and an identical (boomerang) EN 6XXXX, the latter should by preference be referenced. Emphasis should be put on this fact by stressing that this case merely reflects a renumbering action (see also Annex 3 and Annex 4); ∗ in this same case no dow shall be fixed for the adopted boomerang EN 6XXXX. It remains however the prerogative of BT to fix a dow where appropriate, on a case by case basis; ∗ once a boomerang standard has ended its journey, only that EN 6XXXX can be amended or revised.
Sample 1
AutoNDA by SimpleDocs

Related to Development Time

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Diligence Novartis shall dedicate commercially reasonable efforts, during each [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards the next clinical Development milestone or approval milestone, as described in Sections 7.4.2 or 7.4.3, respectively. If Novartis (itself or through its Affiliates or sublicensees) fails to dedicate commercially reasonable efforts, during any [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards such next milestone, then any dispute regarding Novartis’ failure of development diligence with respect to such Profile shall be resolved in accordance with Article 13.

  • Commercialization Plans As soon as practicable after formation of the JCC (following Acucela’s exercise of an Opt-In Right under Section 3.1), the JCC shall prepare and approve the initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation (and, if applicable, any New Formulation or Other Indication Product) in the Territory. The Parties shall use Commercially Reasonable Efforts to ensure that such initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation is consistent with the general Commercialization Plan outline set forth in Exhibit C attached hereto and incorporated herein (the “General Commercialization Plan Outline”). The JCC shall prepare and approve a separate Commercialization Plan for Commercialization of Licensed Product for the Initial Indication in the Initial Formulation in the Territory and for Commercialization of each Other Indication Product and New Formulation (if any) in the Territory, and shall update and amend each Commercialization Plan not less than annually or more frequently as needed to take into account changed circumstances or completion, commencement or cessation of Commercialization activities not contemplated by the then-current Commercialization Plan. Amendments and revisions to the Commercialization Plan shall be reviewed and discussed, in advance, by the JCC, and Otsuka agrees to consider proposals and suggestions made by Acucela regarding amendments and revisions to the Commercialization Plan. Any amendment or revision to the Commercialization Plan that provides for an increase or decrease in the number of FTEs for any Phase 3b Clinical Trials or Post-Approval Studies as compared to the previous version of the Commercialization Plan, or that provides for addition or discontinuation of tasks or activities as compared to the previous version of the Commercialization Plan, or that moves forward the timetable for activities reflected in the Commercialization Plan, shall provide for a reasonable ramp-up or wind-down period, as applicable, to accommodate a smooth and orderly transition of Commercialization activities to the amended or revised Commercialization Plan. Each Commercialization Plan shall identify the goals of Commercialization contemplated thereunder and shall address Commercialization (including Co-Promotion) activities related to the Licensed Product (including, if applicable, any Other Indication Product), including:

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Initial Development Plan Not later than the Effective Date, Licensee shall have provided Merck with an initial Development plan for the Licensed Product in the Field in the Territory, which shall be incorporated as part of this Agreement as Attachment 3.02(a) (as may be amended in accordance with this Agreement, the “Development Plan”). **CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND WILL BE FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO A CONFIDENTIAL TREATMENT REQUEST.

  • Development Records Each Party shall maintain complete, current and accurate records of all Development activities conducted by it hereunder, and all data and other information resulting from such activities. Such records shall fully and properly reflect all work done and results achieved in the performance of the Development activities in good scientific manner [*]. Each Party shall document all non-clinical studies and clinical trials in formal written study reports according to applicable Laws and national and international guidelines (e.g., ICH, GCP, GLP, and GMP). Each Party shall have the right to review and copy such records maintained by the other Party at reasonable times and to obtain access to the original [*].

  • Development 3.3 Within twenty (20) Working Days after the Commencement Date and in accordance with paragraphs 3.10 to 3.12 (Amendment and Revision), the Contractor will prepare and deliver to the Authority for approval the full and final Security Plan which will be based on the draft Security Plan set out in Appendix B.

Time is Money Join Law Insider Premium to draft better contracts faster.